Lower-Risk MDS Population Has Enduring RBC-TI Following Imetelstat Therapy
Imetelstat treatment in phase 3 IMerge study showed sustained red blood cell transfusion independence (RBC-TI) in lower-risk MDS patients without OS detriment. 83% of responders achieved RBC-TI for at least 8 weeks, with median durations of 51.6 weeks vs 13.3 weeks in placebo. FDA approved imetelstat in June 2024 for low-to intermediate-1–risk MDS with transfusion-dependent anemia. Further studies needed to clarify imetelstat's mechanism and longer-term responses.
Related Clinical Trials
Reference News
Imetelstat treatment in phase 3 IMerge study showed sustained red blood cell transfusion independence (RBC-TI) in lower-risk MDS patients without OS detriment. 83% of responders achieved RBC-TI for at least 8 weeks, with median durations of 51.6 weeks vs 13.3 weeks in placebo. FDA approved imetelstat in June 2024 for low-to intermediate-1–risk MDS with transfusion-dependent anemia. Further studies needed to clarify imetelstat's mechanism and longer-term responses.